SCHEDULE 13G: Investment Firms Disclose 8.6% Stake in BriaCell Therapeutics Corp.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed an 8.6% beneficial ownership stake in BriaCell Therapeutics Corp., totaling 489,200 common shares.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (collectively, 'Reporting Persons') have filed a Schedule 13G with the SEC regarding their beneficial ownership in BriaCell Therapeutics Corp.
• The Reporting Persons collectively beneficially own 489,200 common shares of BriaCell Therapeutics Corp.
• This ownership represents 8.6% of BriaCell Therapeutics Corp.'s common shares outstanding.
• Heights Capital Management, Inc. serves as the investment manager for CVI Investments, Inc. and exercises shared voting and dispositive power over these shares.
• The event triggering this filing occurred on April 24, 2025.
• As of April 28, 2025, BriaCell Therapeutics Corp. had 5,715,407 common shares outstanding, excluding shares underlying pre-funded and other warrants, as indicated in the company's prospectus.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the company's perceived value or outlook, thus maintaining a neutral sentiment.

Positives

• A significant institutional investor, CVI Investments, Inc., maintains an 8.6% stake in BriaCell Therapeutics Corp., indicating continued institutional interest in the company.

Risks

• The Reporting Persons disclaim any beneficial ownership of the shares except for their pecuniary interest therein.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Future Outlook

NA

Management Comments

• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.
• Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing is a standard disclosure of significant ownership by institutional investors in a publicly traded company, common across all industries, including the biotechnology sector where BriaCell Therapeutics Corp. operates. It provides transparency regarding the ownership structure.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a large investor's stake in the company.
• Management: Offers clarity on the beneficial ownership structure and the passive nature of the reported stake, as the investors disclaim intent to influence control.

Key Dates

Keywords

BriaCell Therapeutics Corp., CVI Investments Inc., Heights Capital Management Inc., Schedule 13G, beneficial ownership, common shares, institutional investment, SEC filing